Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice.
about
Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa.Adherence to and penetration of human intestinal Caco-2 epithelial cell monolayers by Pseudomonas aeruginosa.Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.Mechanisms of action and clinical application of macrolides as immunomodulatory medications.Evaluation of susceptibility of gram-positive and -negative bacteria to human defensins by using radial diffusion assayEfficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in miceEffects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosaPseudomonas aeruginosa serA Gene Is Required for Bacterial Translocation through Caco-2 Cell Monolayers.Virulence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in vitro and in vivo.Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in miceImmunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice.Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa.In vivo production of exotoxin A and its role in endogenous Pseudomonas aeruginosa septicemia in mice.Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa.Interleukin-1 deficiency in combination with macrophage depletion increases susceptibility to Pseudomonas aeruginosa bacteremia.
P2860
Q33751103-2E6F3316-21DD-4578-830A-2747B1FC12C5Q33752721-264FD90B-F445-4677-9B15-004B1FD133D7Q33938255-57951B56-2A5F-455C-AEEC-31789EF91A1FQ33983140-063913AF-10D1-415D-B327-CEC7BF230800Q35127823-BC6E4706-ECF4-42DA-AE3C-5C33C0C43E40Q35635891-C4EDE0C5-15CB-48CB-BF17-51ADBF37DBF4Q35811035-E14C4184-CDCE-4F86-ABBE-874726D59705Q36238226-7330BA44-2641-404E-B8E2-DE12A41B2497Q37734720-B6495125-CBEE-4D63-BA94-68430A36CC68Q39559384-FB0D0D21-6F51-475F-8547-960D45288439Q39783620-F1E5B385-4D28-490F-8906-822214C889A8Q39881823-8A4CFD26-86B5-4651-A172-24A93FC1B795Q40267457-A493A41A-D836-40DF-9039-AAF0EA339A2FQ40721285-89829E6A-7B9D-42DA-988F-50D8719FAF59Q43287032-A26B5743-2BC1-491F-A58B-1C87FEEABB68
P2860
Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Efficacy of erythromycin lacto ...... aeruginosa bacteremia in mice.
@en
Efficacy of erythromycin lacto ...... aeruginosa bacteremia in mice.
@nl
type
label
Efficacy of erythromycin lacto ...... aeruginosa bacteremia in mice.
@en
Efficacy of erythromycin lacto ...... aeruginosa bacteremia in mice.
@nl
prefLabel
Efficacy of erythromycin lacto ...... aeruginosa bacteremia in mice.
@en
Efficacy of erythromycin lacto ...... aeruginosa bacteremia in mice.
@nl
P2093
P2860
P356
P1476
Efficacy of erythromycin lacto ...... aeruginosa bacteremia in mice.
@en
P2093
Hirakata Y
Matsumoto T
Yamaguchi K
P2860
P304
P356
10.1128/AAC.36.6.1198
P407
P577
1992-06-01T00:00:00Z